The price of Neumora Therapeutics Inc (NASDAQ:NMRA) shares last traded on Wall Street rose 10.15% to $2.17.
NMRA stock price is now -79.57% away from the 50-day moving average and -80.81% away from the 200-day moving average. The market capitalization of the company currently stands at $386.18M.
With the price target reduced from $29 to $4, RBC Capital Mkts Downgraded its rating from Outperform to Sector Perform for Neumora Therapeutics Inc (NASDAQ: NMRA). On November 05, 2024, JP Morgan Downgraded its previous ‘Overweight’ rating to ‘Neutral’ on the stock reducing its target price from $18 to quote $15, while ‘H.C. Wainwright’ rates the stock as ‘Buy’
In other news, Fust Matthew K, Director sold 14,049 shares of the company’s stock on Oct 18 ’24. The stock was sold for $239,319 at an average price of $17.03. Upon completion of the transaction, the Director now directly owns 20,100 shares in the company, valued at $43617.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 17 ’24, Director Fust Matthew K sold 7,739 shares of the business’s stock. A total of $131,643 was realized by selling the stock at an average price of $17.01. This leaves the insider owning 20,100 shares of the company worth $43617.0. A total of 65.85% of the company’s stock is owned by insiders.
During the past 12 months, Neumora Therapeutics Inc has had a low of $1.83 and a high of $21.00. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 10.98, and a quick ratio of 10.98. The fifty day moving average price for NMRA is $10.621 and a two-hundred day moving average price translates $11.310675 for the stock.
The latest earnings results from Neumora Therapeutics Inc (NASDAQ: NMRA) was released for 2024-09-30. The company reported revenue of $76.65 million for the quarter, compared to $56.86 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 34.79 percent.
